Fig. 4.

Progression-free survival. a PFS of CR patients (n = 68)—Of 68 patients achieving CR, forty progressed, while 28 (censored) remained progression-free. The median PFS was 3.14 years with 95% CI of (2.48, 5.18). The 1, 5 and 10 years PFS rates were 87, 51 and 38%, respectively; b PFS by MTX continuation after CR—For patients who ceased MTX within two cycles of CR (dotted line), the median PFS is 2.86 years with 95% CI of (1.32, upper not reached). The 1, 2 and 5 years rate are 79, 63, and 29% respectively. For patients who continued MTX after CR (solid line), the median PFS is 5 years with 95% CI of (3, 9.2). The 1, 2 and 5 years rate are 90, 67, and 43% respectively. PFS progression-free survival; 95% CI 95% confidence interval